DGAP-News: Sangui BioTech International Inc.: - Granulox with the Annual Advanced Wound Care Award honored

Sangui BioTech:

- Granulox with the Annual Advanced Wound Care Award honored

Witten, May, 22 2018: As part of this year's European Wound Management Association (EWMA), the most important conference in the field of wound care in Europe, which took place in Krakow, Poland from 9 to 11 May, Sastomed GmbH was awarded its third Annual Advanced Wound Care Innovation Award from Alira Health. Sastomed GmbH received this award for the development and marketing of the Sangui licensed wound spray Granulox. Granulox prevailed in the final against three competitors. The prestigious jury praised Granulox for being the most innovative product in the field of wound care, which has successfully proven its clinical effectiveness since its market launch.

"My team put a lot of efforts behind our patented technology to produce a highly purified, stabilized protein-solution with a very high ease of use. Now it's possible to significantly improve wound healing by additional oxygen supply for patients all around the globe. The robust technology makes this product feasible not only for patients in highly sophisticated health-care settings but also enhances healing in millions of sufferers in developing countries. We're excited and honored that Granulox was recognized with this highly prestigious award." says Michael Sander, Managing Director of Sastomed GmbH.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.